Product details
Background：Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a.
• Sutimlimab: First Approval., PMID:35412113
• Complement Component 1, s Subcomponent Overexpression is an Independent Poor Prognostic Indicator in Patients with Urothelial Carcinomas of the Upper Urinary Tract and Urinary Bladder., PMID:27471555
• Genetic studies of low-abundance human plasma proteins. VII. Heterogeneity of the C1S subcomponent of the first complement component., PMID:3331643
• Structural basis of the C1q/C1s interaction and its central role in assembly of the C1 complex of complement activation., PMID:23922389
• C1 inhibitor: different mechanisms of reaction with complement component C1 and C1s., PMID:2055603
• Fluid-phase interaction of C1 inhibitor (C1 Inh) and the subcomponents C1r and C1s of the first component of complement, C1., PMID:6282262
• Human complement component C1s. Partial sequence determination of the heavy chain and identification of the peptide bond cleaved during activation., PMID:3007145
• Is there a link between genetic defects in the complement cascade and Porphyromonas gingivalis in Alzheimer’s disease?, PMID:31893014
• Periodontal Ehlers-Danlos Syndrome Is Caused by Mutations in C1R and C1S, which Encode Subcomponents C1r and C1s of Complement., PMID:27745832
• Activation of the first component of human complement, C1, by monoclonal antibodies directed against different domains of subcomponent C1q., PMID:3486914
